Selected publications
-
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood.
2019
Academic Article
GET IT
Times cited: 11 - Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Academic Article GET IT
-
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood.
2017
Academic Article
GET IT
Times cited: 259 -
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Cell Cycle.
2012
Academic Article
GET IT
Times cited: 34 -
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Cell Cycle.
2011
Academic Article
GET IT
Times cited: 31 -
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Cell Cycle.
2011
Academic Article
GET IT
Times cited: 30 -
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison.
Biochemical Pharmacology.
2008
Academic Article
GET IT
Times cited: 26 -
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: A preclinical study.
Blood.
2008
Academic Article
GET IT
Times cited: 88